Program
Sirolimus Topical Gel PTX-022
Its studies are mostly in Lymphangioma · Basal Cell Nevus Syndrome, led by Palvella Therapeutics.
Furthest: phase 3, since Apr 2, 20196 company-led studies, 2 open or runningNext primary completion: Aug 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Palvella Therapeutics | 62 open or running | phase 3since Apr 2, 2019 | Apr 2, 2019 | Aug 2027phase 2 · NCT07552077 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 2, 2019First study: phase 3 study in Pachyonychia CongenitaFirst studyNCT03920228 · 73 enrolled · United States
- Mar 6, 2020Phase 3 study in Pachyonychia CongenitaNCT04520750 · 36 enrolled · United States
- May 14, 2021Phase 2 study in Basal Cell Nevus SyndromeNCT04893486 · 73 enrolled · United States, United Kingdom
- Sep 8, 2021Phase 2 study in LymphangiomaNCT05050149 · 12 enrolled · United States
- Nov 8, 2022Phase 3 study in Pachyonychia CongenitaNCT05643872 · 45 planned · United States
- Apr 20, 2026Phase 2 study in AngiokeratomaNCT07552077 · 15 planned · United States
Ahead
- Aug 2027Primary completion: phase 2 study in AngiokeratomaNCT07552077
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07552077Angiokeratoma · United States | 2 | Recruiting | Aug 2027 | 15 |
| NCT05643872Pachyonychia Congenita · United States | 3 | Recruiting | Oct 2023 | 45 |
| NCT05050149Lymphangioma · United States | 2 | Completed | Nov 15, 2022 | 12 |
| NCT04893486Basal Cell Nevus Syndrome · United States, United Kingdom | 2 | Completed | Mar 13, 2023 | 73 |
| NCT04520750Pachyonychia Congenita · United States | 3 | Completed | Jun 30, 2021 | 36 |
| NCT03920228Pachyonychia Congenita · United States | 3 | Completed | Sep 19, 2020 | 73 |
How it is read
Names in the registry
- “PTX-022”, 6 entries
Conditions, from the studies’ own filings
- Lymphangioma, 1 study
- Basal Cell Nevus Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.